On April 27, the "National Action for Zero-level Prevention of Cardiovascular Diseases" was launched in Beijing, guided by the National Public Nutrition Improvement Project Office, co-organized by the China Industry-Academic-Research Cooperation Promotion Association's Clinical Nutrition Collaborative Innovation Platform and Metabolic Disease Prevention and Control Collaborative Innovation Platform, and hosted by Beijing Yisheng Haomei Health Management Center.

This activity aims to explore the scientific research results of the integration of fermented red citrus food science with clinical medicine and fermented traditional Chinese medicine, advocate the new concept of "zero-level prevention", and actively curb the occurrence of cardiovascular and cerebrovascular diseases such as vascular sclerosis, plaque progress, and dyslipidemia.

During the event, the "Red Quostatin Intervention in Real-World Research on Cardiac and Cerebrovascular Diseases" project was launched. It is understood that the study covers 10 provinces and cities across the country, and will include 100,000 dyslipidemia and high-risk groups. The intervention plan is to compare the efficacy, safety and long-term prognosis of the red trastatin family and traditional statins, focusing on the incidence of cardiovascular events, improvement of vascular elasticity, and the impact of liver and renal function.

At the launch ceremony, Yu Xiaodong, director of the National Public Nutrition Improvement Project Office, said: "Through international cutting-edge evaluation methods such as 'carotid endometrial thickness grading', we can detect hidden dangers of vascular health earlier. This project is to promote the forward movement of the prevention and treatment barriers, so that health management will shift from 'treatment of diseases' to 'disease-free prevention'."

Professor Ma Fang of Peking Union Medical College Hospital of the Chinese Academy of Medical Sciences emphasized at the launch ceremony: "The traditional three-level prevention system can no longer meet the current prevention and control needs. 'Zero-level prevention' is to intervene before the disease risk factors are formed, and it is the real 'prevention of disease'. This is not only an innovation in the medical model, but also a revolution in health concepts."

Professor Liu Xuanzhong of Beijing Tiantan Hospital Affiliated to Capital Medical University explained the factors and mechanisms of atherosclerosis. He said that to strengthen the education on "zero-level prevention and control" of cardiovascular and cerebrovascular diseases and improve the people's awareness of disease prevention and control, it is recommended to move the zero-level prevention threshold forward, and move the primary and secondary prevention that have become necessary for cardiovascular and cerebrovascular to level 0.5 prevention, and establish new standards for cardiovascular and cerebrovascular safety prevention for patients with first and second-level cardiovascular and cerebrovascular diseases.

Professor Wang Fang, director of the Department of Cardiology at Beijing Hospital, explained the necessity of "zero-level prevention" of cardiovascular and cerebrovascular diseases. She pointed out that it is very important to add natural red trastatin small molecule family to comprehensive management to prevent the progress of arteriosclerosis. Professor Peng Guoqiu of the People's Liberation Army General Hospital explained the research progress of Red Music as a traditional Chinese medicine from ancient times to the present. Professor Kong Bo, director of Fuwai Hospital of the Chinese Academy of Medical Sciences, made a speech on "New Progress in Reversal of Arteriosclerosis Sclerosis Plaques and the Application of Red Tastatin in Patients with Hyperlipidemia".

Professor Zou Aibiao, director of the Medical Nutrition Therapy Research Center of Tsinghua Strait Research Institute, is the first scientist in my country to preside over the development of statin drugs. From 1993 to 2005, he presided over the development of a series of innovative drugs such as atorvastatin (trade name "Ale"), filling the gap in China and creating a new era of development of cardiovascular and cerebrovascular drugs in China. Professor Zou highly praised the research on red trastatin by Professor Zhang Maoliang's team at Peking University, and personally went to Zhuozhou Biopharmaceutical Company in Hebei for technical guidance. Through innovative improvements to the traditional solid-state fermentation process, the research team has achieved three breakthrough progress: establishing a small molecule statin stability regulation system, developing a directional enhancement technology for biological activity, and revealing the mechanism of multi-target synergy.

Professor Li Jingren of China's clinical nutrition collaborative innovation platform introduced: "We will carry out a series of activities such as the "Healthy Vascular Tour of China", including the health commitment of millions of families, the creation of healthy kitchens, and the cultivation of community health ambassadors, etc., so that a healthy lifestyle can be deeply rooted in the hearts of the people." Han Zhao, general manager of Beijing Yisheng Haomei Health Management Center, said that in the future, the popular science publicity and training of vascular health will be carried out, the public welfare lectures on "Vascular Health, Nutrition First", and the experts in the disciplines of cardiovascular and cerebrovascular and clinical nutrition will enter the community, and a series of public welfare activities such as zero-level prevention lectures on cardiovascular and cerebrovascular diseases will be carried out.

[Editor in charge: Sun Hui]